Cytokinetics, Incorporated (NASDAQ:CYTK) is a biopharmaceutical company focused on developing muscle biology-driven treatments. The company is currently under investigation by Faruqi & Faruqi, LLP for potentially misleading investors about the regulatory timeline for their drug, aficamten. This investigation centers on the absence of a Risk Evaluation and Mitigation Strategy (REMS) in their New Drug Application (NDA), which could delay FDA approval.

During a May 6, 2025 earnings call, it was disclosed that Cytokinetics had several pre-NDA meetings with the FDA. Despite these discussions, the company submitted the NDA without a REMS, opting for labeling and voluntary education materials instead. This decision misled investors, leading to inflated stock prices and significant losses when the truth was revealed. Investors who bought shares between December 27, 2023, and May 6, 2025, are urged to contact Faruqi & Faruqi, LLP.

On November 11, 2025, Kaye Edward M. MD, a director at Cytokinetics, sold 5,175 shares at $65.08 each. This transaction left him with 9,977 shares. The stock is currently priced at $67.06, showing a slight increase of 0.93% or $0.62.

The stock's price has fluctuated between $65.33 and $67.98 today, with the latter being its highest in the past year. Cytokinetics' market capitalization stands at approximately $7.98 billion, with a trading volume of 813,094 shares. The stock's lowest price in the past year was $29.31. Investors affected by the misleading statements are encouraged to seek legal counsel, with the deadline for lead plaintiff applications set for November 17, 2025. Faruqi & Faruqi, LLP has a strong track record of recovering funds for investors.